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PDefining a Rational Approach to Screening
for Cardiovascular Risk in Asymptomatic Patients
Philip Greenland, MD, Donald Lloyd-Jones, MD, SCM
Chicago, Illinois
Screening for coronary artery disease or for other forms of cardiovascular disease (CVD), is a superficially attrac-
tive idea that has been proposed by many cardiovascular experts. However, guidelines panels that employ medi-
cal outcomes and evaluation of a full range of benefits, risks, and harms of screening have repeatedly advised
against the adoption of screening programs for CVDs. In this commentary, we discuss the limitations of the pre-
dictive capacity of selected cardiovascular screening tools. Possible harms and risks of screening tools are also
discussed, and the conclusion is reached that available evidence does not provide support for adoption of a
strategy of routine screening of asymptomatic people for CVD with available testing tools or devices. More evi-
dence is needed to justify a policy of screening for CVD. (J Am Coll Cardiol 2008;52:330–2) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.029s
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vcreening for presence of atherosclerotic coronary artery dis-
ase (CAD) or cardiovascular disease (CVD) in general, as
roposed by Cohn and Duprez in this issue of the Journal (1),
s superficially attractive. The widely accepted World Health
rganization-defined criteria for screening (2) for disease in
edicine are shown in Table 1, and CVD satisfies many of
hese criteria. However, as we discuss in the following text,
creening for CVD does not meet several of the criteria
onsidered essential for screening tests (Table 1), leading us to
ifferent conclusions than Cohn and Duprez (1).
Despite the immediate appeal of cardiovascular screening
ith such common tests as coronary calcium measurement
3), vascular ultrasound for intimal-medial thickness (4), or
host of other tests as described by Cohn and Duprez (1),
outine screening for subclinical CAD/CVD has met with
early universal negative recommendations by expert panels
5–7). If medical screening of this type is feasible and
ell-accepted for certain forms of cancer and patients are
illing to purchase screening tests even without a personal
hysician’s referral (8), what is the problem?
Although Cohn and Duprez (1) criticize traditional
ardiovascular risk factors as being poorly predictive of
ardiovascular events, they do not consider the substantial
imitations of prediction with the screening tests that they
dvocate. A critical assessment of one of the most promising
f the methods for early detection of CAD, coronary artery
alcium (CAC) measured by rapid computed tomography,
rovides enlightening insights into the negatives of such
rom the Departments of Preventive Medicine and Medicine, Northwestern Uni-
ersity, Feinberg School of Medicine, Chicago, Illinois.i
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ccepted April 21, 2008.creenings. On the one hand, recent reports from MESA
Multi-Ethnic Study of Atherosclerosis) demonstrated con-
incingly that CAC testing is predictive of coronary events
n whites, blacks, Hispanics, and Chinese-Americans, and
ESA found that increased CAC scores are predictive over
nd above traditional risk factors in both men (9) and
omen (9,10). Despite showing unusually strong hazard
atios for major coronary events ranging as high as approx-
mately 7 compared with a reference group with CAC  0,
ESA results also showed that CAC has remarkably poor
ositive predictive value for near-term events regardless of
he cutoff chosen for a positive test (9). Depending on the
utoff chosen for a positive test, sensitivity is also relatively
oor. As shown in Table 2, for a cutoff value of CAC 0 as
he definition of a positive test in MESA, sensitivity for
ear-term events was 91% but specificity was only 51% in
his population of relatively low-risk people (major coronary
vent rate during 3.9 years of median follow-up was slightly
bove 1%, with estimated 10-year risk extrapolated to
pproximately 5%) (9). With a cutoff of CAC 0 for a
ositive test, positive predictive value was only 2%. Further-
ore, the positive predictive value would be substantially
ower in younger populations than in the MESA cohort,
hich had a mean age of 62 years.
Screening, by definition, involves the routine evaluation
f asymptomatic people, and detection, not exclusion, of
isease is the primary goal. This certainly seems to be the
xpected outcome of the approach proposed by Cohn and
uprez (1). In MESA (9), when a more stringent cutoff of
AC100 is used, sensitivity for near-term major coronary
vents drops markedly to only 63%, and positive predictive
alue remains low at 3.5%. Thus, although hazard ratios are
mpressive for CAC and far exceed those for carotid
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July 29, 2008:330–2 Screening for Cardiovascular Riskntima-media thickness (4,11), C-reactive protein (9,12), or
ny of the traditional risk factors for CHD (9), positive
redictive values for CAC measurement are poor. Indeed,
ven with these impressive hazard ratios, the C-statistic,
hich is a measure of discrimination, improves only from
.79 in MESA for risk factors alone as a predictor of CHD
vents to 0.83 for risk factors plus CAC score. Although
his increase in the C-statistic is consistent with improved
iscrimination, the value of 0.83 indicates that CAC scoring
n top of risk factor measurement still has important
imitations in prediction of events—another fact ignored by
ohn and Duprez (1).
An important distinction between cancer screening tests
nd those available for cardiovascular risk assessment is
vailability (or lack for CVD tests) of cost-effectiveness or
utcomes data. We do not have a full understanding of the
isks of CVD screening; nor do we have a full accounting of
enefits and costs. These issues have been the major cause
or lack of endorsement of such tests as coronary calcium
coring for the general population by groups that include the
.S. Preventive Services Task Force (USPSTF) (5) and the
.K. National Health Service Research and Development
ealth Technology Assessment Program (6). Not only do
e lack evidence that these sorts of screening confer a
enefit, we know that there is also risk of harm. Harms of
creening include false reassurance due to a test with low
ensitivity, anxiety due to a false positive test, and in the case
f certain tests such as mammography and coronary com-
uted tomography, radiation exposures as well as the addi-
ional anxiety and possible risks due to discovery and
valuation of incidental findings that result in considerable
dded medical expense and invasive procedures (13). The
dded burden of follow-up invasive angiography (that might
r might not be necessary) observed after coronary calcium
coring is an object lesson that screening for vascular disease
s not without obvious although often neglected hazards.
There should be no double-standard in comparing car-
iovascular screening tests and cancer screening tests. As
orld Health Organization Criteria for Screening
Table 1 World Health Organization Criteria for Screening
● The condition sought should be an important health problem for the individual
and community.
● There should be an accepted treatment or useful intervention for patients with
the disease.
● The natural history of the disease should be adequately understood.
● There should be a latent or early symptomatic stage.
● There should be a suitable and acceptable screening test or examination.
● Facilities for diagnosis and treatment should be available.
● There should be an agreed policy on whom to treat as patients.
● Treatment started at an early stage should be of more benefit than treatment
started later.
● The cost should be economically balanced in relation to possible expenditure
on medical care as a whole.
● Case finding should be a continuing process and not a once and for all project.
dapted, with permission, from Wilson (2).oted by Cohn and Duprez (1), mammography is recom-
aended by the USPSTF, with a
uality rating of B (i.e., this level
ecommends that clinicians pro-
ide this service to eligible pa-
ients on the basis of at least fair
vidence from clinical trials that
he service improves important
ealth outcomes and concludes
hat benefits outweigh harms).
vidence is strongest for women
ges 50 to 69 years, the age group
enerally included in screening
rials (14). With the identical review standards, the USPSTF
5) recommended against routine screening with resting
lectrocardiography, exercise treadmill test, or rapid com-
uterized tomography scanning for coronary calcium for
ither the presence of severe coronary artery stenosis or the
rediction of coronary heart disease events in adults at low
isk for CHD events (i.e., screening of the general asymp-
omatic population). The USPSTF concluded that there
as at least fair evidence that these tests were ineffective or
hat harms outweigh benefits (5).
The preceding discussion points regarding coronary cal-
ium measurement pertain to what is arguably the best and
est-studied screening test currently available for detecting
ubclinical CAD. Our concerns are magnified and far more
eaningful when applied to measures with large potential
ources of error (relative to signal), such as carotid intima-
edia thickness and arterial stiffness measures. There are
ubstantial difficulties associated with broad application of
hese newer technologies in clinical practice, including:
echnical issues, especially technician-dependence of scan-
ing; reader error and bias; and lack of agreement on the
ost appropriate parameters to be measured and the best
nstruments to use. It is also largely unclear how often (if
ver) any of the screening tests proposed by Cohn and
uprez (1) should be repeated or what a meaningful change
n these values is.
In our judgment, additional studies of screening strate-
ies, including patient outcomes, are needed before recom-
est Criteria foreasu ement of CAC From MESA
Table 2 Test Criteria forMeasurement of CAC From MESA
For a testing cutoff of CAC 0 as a positive test:
● Sensitivity: 81 of 89  0.91
● Specificity: 3,403 of 6,635  0.51
● Positive predictive value: 81 of 3,313  0.02
● Negative predictive value: 3,403 of 3,411  0.997
For a testing cutoff of CAC 100 as a positive test:
● Sensitivity: 56 of 89  0.63
● Specificity: 5,106 of 6,635  0.77
● Positive predictive value: 56 of 1,585  0.035
● Negative predictive value: 5,106 of 5,139  0.99
n the basis of 89 major coronary events in 3.9 years median follow-up in 6,724 men and women
Abbreviations
and Acronyms
CAC  coronary artery
calcium
CAD  coronary artery
disease
CHD  coronary heart
disease
CVD  cardiovascular
diseaseges 45 to 84 years at baseline examination. Adapted, wi
CAC  coronary artery calcium; MESA  Multi-Ethnic Stth permission, from Detrano et al. (9).
udy of Atherosclerosis.
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Screening for Cardiovascular Risk July 29, 2008:330–2ending any form of routine CVD screening for the
symptomatic patient. As an example of the complexity of
his issue, a study of coronary calcium screening among
rmy personnel (15), which attempted to use knowledge of
ubclinical CAD to motivate patients to make evidence-
ased changes in risk factors, indicated that such knowledge
as not associated with improvement in modifiable cardio-
ascular risk at 1 year. In that study (15), case management
as superior to usual care in the treatment and control of
isk factors. The “obvious” and expected benefits of screen-
ng did not occur. Although not definitive throughout the
ntire spectrum of possible patients and potential levels of
ardiovascular risk, these findings demonstrate that we
annot assume clinical benefit simply because the tests we
mploy are feasible and have anatomical or physiological
ace validity.
In conclusion, we agree with the USPSTF (16,17) that
he best approach at this time for CVD assessment and
revention lies in routine testing for traditional coronary
isk factors. As the USPSTF has noted (16,17), this is a
roven approach to identifying a group of patients who can
enefit from preventive treatments shown in clinical trials of
lood pressure lowering and cholesterol lowering. In con-
rast to the more controversial forms of screening previously
iscussed, the USPSTF gave blood pressure and cholesterol
esting and screening its highest grade of quality—an “A”
rade. Accordingly, the USPSTF strongly recommends that
linicians routinely provide these risk-factor measurements
o eligible patients on the basis of solid evidence that these
ervices improve important health outcomes and the bene-
ts of such tests substantially outweigh the harms (16,17).
n the basis of the considerations we have discussed, we
elieve this is the best and most rational current approach to
screening” for CAD risk.
eprint requests and correspondence: Dr. Philip Greenland,
orthwestern University, Feinberg School of Medicine, 750
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